Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year, exclusive distribution agreement with Suministros Medicos Multimedicas, based in Caracas, Venezuela, for the distribution of the SonaStar™ Ultrasonic Surgical Aspirator, the BoneScalpel™ Ultrasonic Bone Cutter, and the SonicOne® Ultrasonic Wound Debrider. The agreement provides Suministros with the rights to sell and distribute in Venezuela, and includes minimum purchase requirements.
Suministros, well known in Venezuela for their customer service orientation, has built a reputation as a distributor of state-of-the-art medical devices and capital equipment, with special emphasis on Neurosurgery, Spinal Surgery, and General Surgery.
The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.
The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.
The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.
"Misonix is pleased to add Suministros Medicos Multimedica to our rapidly expanding family of Latin American specialty distributors. Their reputation as a high-profile distributor of advanced medical equipment in Venezuela is well known to us," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We are particularly pleased that they will be selling three of our key products through their well established distribution pipeline."
Maleic acid treatment enhances bacterial cellulose for bone tissue engineering